Major cytochrome P-450 families: Implications in health and liver diseases

Acta Gastro-Enterologica Belgica

Volumn 60, Issue 1, 1997, Pages 2-10

  Horsmans, Y ^a,b  

^a Gastroenterology Department   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFLAMINE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; GESTODENE; GUANOXAN; MEVINOLIN; MONOAMINE OXIDASE INHIBITOR; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PERHEXILINE; PHENFORMIN; PHENYTOIN; PROGUANIL; PROPRANOLOL; RIFAMPICIN; TAMOXIFEN; TERFENADINE; TIENILIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DRUG; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LIVER DISEASE; LIVER FUNCTION; PHARMACOGENETICS; REVIEW; AWARDS AND PRIZES; BELGIUM; CLASSIFICATION; DRUG INTERACTION; ENZYME INDUCTION; ENZYMOLOGY; GASTROENTEROLOGY; GENETICS; LIVER; METABOLISM; PHYSIOLOGY; TOXIC HEPATITIS;

ARYL HYDROCARBON HYDROXYLASES; AWARDS AND PRIZES; BELGIUM; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; GASTROENTEROLOGY; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER DISEASES; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 0030887121     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. ANDERSSON T., REGARDH C.G., DAHL-PUUSTINEN M,L., BERTILSSON L Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monitoring, 1990, 12 . 415-416.
2. ANDERSON K E , MC CLEERY R.B., VESELL E.S., VICKERS F.F., KAPPAS A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology, 1991, 13 : 941-946.
3. ASFORTH E.I.L., CARLILE D.J., CHENERY R., HOUSTON J.B. Prediction of in vivo disposition from in vitro systems : clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J. Pharmacol Exp. Ther., 1995, 274 : 761-766.
4. AYOMA T., YAMANO S., GUZELIAN P.S., GELBOIN H.V., GONZALES F.J. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxiri B1 Proc Natl. Acad. Sci. USA, 1990, 87 4790-4793.
5. BAILEY D.G., SPENCE J.D., MUNOZ C., ARNOLD J.M O. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337 : 268-269.
6. BERTILSSON L. Geographical interracial differences in polymorphic drug oxidation. Current status of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 Clin. Pharmacokinet., 1995, 29 : 192-209.
7. BOURDI M., LARREY D., NATAF J., BERNUAU J., PESSAYRE D , IWASAKI M , GUENGERICH F P., BEAUNE P Anti-liver endoplasmic reticulum auto-antibodies are directed against human liver cytochrome P-4501A2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest , 1990, 85 : 1967-1973
8. BRANCH R.A., HERBERT C.M., READ A.E. Determinants of serum antipyrine half-lives in patients with liver disease Gut, 1973, 14 : 569-573
9. BRANCH R A. Drugs as indicators of hepatic function. Hepatology, 1982, 14 97-105.
10. BREIMER D D., SCHELLENS J.H.M., SOONS P.A. Nifedipine : variability in its kinetics and metabolism in man. Pharmacol. Ther., 1989, 44 : 334-454.
11. BRODIE B.B , AXELROD J. The fate of antipyrine in man. J. Pharmacol Exp. Ther., 1950, 98 : 97-104.
12. BROLY F., GAEDIGK A., HEIM M , EICHELBAUM M., MORIKE K., MEIER U.A. Debrisoquine/spartein hydroxylation genotype and phenotype : analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology, 1991, 10 : 545-558.
13. BROSEN K., GRAM L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol , 1989, 36 . 537-543.
14. BUCHERT E , WOOSLEY R.L. Clinical implications of variable antiarrythmic drug metabolism Pharmacogenetics, 1992, 2 : 2-11
15. CAPORASO N , LANDI M.T , VINEIS P. Relevance of metabolic polymorphisms to human carcinogenesis evaluation of epidemiologic evidence. Pharmacogenetics, 1991, 1 . 4019-4024.
16. CAKALOGLU Y., TREDGER J M , DEVLIN J., WILLIAMS R. Importance of cytochrome P-450111A activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology, 1994, 20 309-316.
17. CHUNG FL , MORSE M.A., EKLIND K.I. New potential chemopreventive agents for lung carcinogenesis of tobacco-specific nitrosamine. Cancer Res , 1992, 52 (Suppl) 2719-2722.
18. CRAIG PL, TAPNER M., FARRELL G.C. Interferon suppresses erythromycin metabolism in rats and human subjects Hepatology, 1993, 17 . 230-235.
19. DAHL M.L., BERTILSSON L. Genetic variable metabolism of antidepressants and neuroleptic drugs in man Pharmacogenetics, 1993, 3 : 61-70.
20. DALY A.K., ARMSTRONG M , MONKMAN S.C., IDLE M E., IDLE J.R. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics, 1991, 1 : 33-41.
21. DANHOF M., VERBEEK R.M.A., VAN BOXTEL C.J., BOEIJINGA J.K., BREIMER D.D. Differential effects of enzyme induction on antipyrine metabolite formation. Br. J Clin Pharmacol., 1982, 13 : 379-386.
22. EICHELBAUM M., SPANNBRUCKER N , STEINCKE B., DENGLER H J Defective N-oxidation of sparteine in man : a new pharmacogenetic defect Eur. J. Clin. Pharmacol., 1979, 16: 183-187.
23. EICHELBAUM M., GROSS A.S. The genetic polymorphism of debrisoquine/ sparteine metabolism - clinical aspects Pharmacol. Ther., 1990, 46 : 377-394.
24. EVANS W.E., RELLING M V Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype : inability of dextrometorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics, 1991, 1 : 143-148.
25. GAEDIGK A., BLUM M., GAEDIGK R , EICHELBAUM M., MEYER U.A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J. Human Genet. 1991, 48 : 943-950
26. GEORGE J., MURRAY M., BYTH K., FARRELL G.C Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995, 21 : 120-128
27. GERBER M., HADZIYANNIS S., VISSOULIS C. et al Hepatitis B antigen. Nature and distribution of cytoplasm antigen in hepatocytes of carriers. Proc. Soc. Exp. Biol. Med , 1974, 154 : 863-866.
28. GEUBEL A.P., PAUWELS S., BUCHET J.P., DUMONT E., DIVE C. Increased cytochrome P-450 dependent function in healthy HB5Ag carriers. Pharmacol Ther., 1987, 33 : 193-196.
29. GONZALEZ F.J., MEYER U.A. Molecular genetics of the debrisoquine/ sparteine polymorphism. Clin. Pharmacol. Ther., 1991, 50 233-238.
30. GUENGERICH F P. Enzymatic oxidation of xenobiotic chemicals. Biochem. Mol Biol , 1990,25 97-153.
31. GUENGERICH F.P., TURVY C.G. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther., 1991, 256 : 1891-1194.
32. HADZIANNIS S.J. The ground-glass hepatocyte An aid to diagnosis, a challenge to pathophysiology In : Berk PD and Chalmers TC (ed) Frontiers in Liver Disease. Thieme-Stratton Inc New York, 1981, 106-121.
33. HALL A.J., WINTER P D., WRIGHT R. Mortality of hepatitis B positive blood donors in England and Wales. Lancet, 1985, 1 : 91-93
34. HAYES K.A., BRENNAN B., CHENERY R., HOUSTON J.B. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos , 1995, 23 : 349-353.
35. HOMBERG J.C., ABUAF N., BERNARD O., ISLAM S., ALVAREZ F., KHALIL S., POUPON R., DARNIS F., LEVY V.G., GRIPPON P., OPOLON P., BERNUAU J., BENHAMOU J.P., ALAGILLE D. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1 a second type of "autoimmune" hepatitis. Hepatology, 1987, 6 : 1333-1339.
36. HORAI Y., ISHIZAKI T , EICHELBAUM M , HASHIMOTO K., CHIBA K., DENGLER H J. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations Xenobiotica, 1988, 18 : 1077-1084.
37. HORAI Y., NAKANO M., ISHIZAKI T., ISHIKAWA K, ZHOU H.H., ZHOU B.J., LIAO C.L., ZHANG L.M. Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subjects . Japanese versus mainland Chinese. Clin. Pharmacol Ther , 1989, 46 . 198-207.
38. HORSMANS Y., DESAGER J.P., PAUWELS S., HARVENGT C. Lack of effect of nifedipine on hepatic mixed function oxidase in man. Fund. Clin. Pharmacol., 1991, 5 : 193-201.
39. HORSMANS Y., DESAGER J.P., HARVENGT C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility ? Biomed. Pharmacother., 1991, 45 : 359-362.
40. HORSMANS Y., STEVENS M., GEUBEL A , HARVENGT C., RAHIER J. Immunoquantification of cytochrome P-450 3A on rat paraffin embedded liver tissue. Liver, 1992, 12 : 344-350.
41. HORSMANS Y., DESAGER J.P., HARVENGT C Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol. Toxicol., 1992, 71 258-261
42. 14C-aminopyrine demethylation capacity after portocaval shunting : a comparative study in patients with and without arterialization of the portal vein. Dig. Dis. Sci., 1993, 38 : 2177-2182.
43. HORSMANS Y. Les hépatites aïgues d'origine médicamenteuse. Gastroenterol. Clin. Biol., 1993, 17 : H25-H30.
44. HORSMANS Y , DESAGER J.P., VAN DEN BERGE V., ABRASSART M., HARVENGT C. Effects of simvastatin and pravastatin on 6 β-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res., 1993, 28 : 243-248.
45. HORSMANS Y., DESAGER J.P., HARVENGT C. Scoparone O-demethylase assay is not useful to differentiate the effects of model inducers of cytochrome P-450 in rabbit and guinea pig liver. Life Sci., 1993, 53 : 421-426.
46. 14C-aminopyrine breath test values in patients with chronic hepatitis C Aliment Pharmacol. Ther., 1994, 8 : 353-355.
47. HORSMANS Y., DESAGER J.P , DAENENS C., HARVENGT C., GEUBEL A.P D-propoxyphene and norpropoxyphene kinetics after the oral administration of d-propoxyphene : a new approach to liver function ? J Hepatol., 1994, 21 : 283-291.
48. HORSMANS Y , LANNES D , PESSAYRE D , LARREY D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium®, a fixed combination drug containing phenobarbital, febarbamate and difebarbamate. J. Hepatol , 1994, 21 : 1075-1079.
49. HORSMANS Y., GEUBEL A.P., PAUWELS S. Reliability of aminopyrine breath test using a single breath collection. Dig. Dis. Sci., 1995, 40 . 1581.
50. 14C-caffeine breath test. Pharmacol. Toxicol., 1995, 77 : 247-249.
51. HORSMANS Y., SALIEZ A., VAN DEN BERGE V., DESAGER J.P., GEUBEL A.P , PAUWELS S., LAMBOTTE L. Liver and intestinal propoxyphene metabolisms . an example of discrepancy in drug presystemic biotransformation in the rat. Hepatology. 1995, 22 (suppl) : 247a (abstract)
52. HORSMANS Y., KANIYNDA J M., DESAGER J P Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects. PharmacoL Toxicol., 1996, 78 : 86-88.
53. HUET P.M., VILLENEUVE J.P. Determinants of drug disposition in patients with cirrhosis Hepatology. 1983, 6 : 913-918.
54. HUKKINEN S.K., VARHE A., OLKKOLA K.T., NEUVONEN P.J. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther., 1995, 58 : 217-231
55. IKAWA S., UEMATSU F , WATANABE K., KIMPARA T., OSADA M., HOSSAIN A., SAGAMI I., KIKUCHI H , WATANABE M. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Pharmacogenetics, 1995, 5: S154-S160.
56. INABA T. Phenytoin : pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol. Ther., 1990, 36 : 341-347.
57. IQBAL S , VICKERS C., ELIAS E. Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes. J. Hepatol , 1990, 11 : 37-42.
58. JOHANSSON I , LUNDQVIST E , BERTILSSON L., MEYER U.A., SJOQVIST F , INGELMAN-SUNDBERG M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl. Acad. Sci. USA, 1993, 90 : 11825-11829
59. JOST G., WALLHAENDER A , VON MANDACH U., PREISIG R. Overnight salivary caffeine clearance : a liver function test suitable for routine use. Hepatology. 1987, 7 : 338-344.
60. KALOW W Pharmacogenetics : heredity and the response to drugs W.B. Saunders, Philadelphia 1992
61. KAWAJIRI T., WATANABE J , EGUCHI H., HAYASHI S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics, 1995, 5 : S70-S73.
62. KATO R., YAMAZOE Y. The importance of substrate concentration in determining P450 therapeutically relevant in vivo. Pharmacogenetics, 1994, 4 359-362
63. KINIRONS M.T., O'SHEA D., DOWNING T.E., FITZWILLIAM A.T., JOELLENBECK L., GROOPMAN J.D., WILKINSON G.R., WOOD A J J Absence of correlations among three putative in vivo probes of human cytochrome P450 3A activity in young healthy men. Clin. Pharmacol Ther , 1993, 54 : 621-629.
64. KLEINBLOESEM C.H., VANBRUMMELEN P., FARBER H., DANHOF M., VERMEULEN N.P.A., BREIMER D.D. Variability in nifedipine pharmacokinetics and dynamics : a new oxidation polymorphism in man. Biochem. Pharmacol., 1984, 33 : 3721-3724
65. KLOTZ U., REIMANN I. Delayed clearance of diazepam due to cimetidine. N. Engl. J. Med., 1980, 302 1012-1014.
66. KNODELL R.G., BROWNE D.G , GWOZDZ G.P , BRIAN W.R., GUENGERICH F.P. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology, 1991, 101: 1680-1691
67. KOLARS J.C., SCHMIEDLIN-REN P., SCHUETZ J.D., FANG C., WATKINS P.B Identification of rifampicin-inducible P450IIIA (CYP3A4) in human small bowel enterocytes. J. Clin. Invest., 1992, 90 : 1871-1878.
68. KRONBACH T., FISCHER V., MEYER U A. Cyclosporine metabolism in human liver - identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol Ther , 1988, 43 630-635
69. KÜPFER A., PREISIG R. Pharmacogenetics of mephenytoin . a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol., 1984, 26 . 753-759
70. KUPFER A , BRANCH R.A. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin. Pharmacol. Ther, 1985, 38 : 414-418.
71. LARREY D., TINEL M., AMOUYAL G., FRENEAUX E., BERSON A., FOUIN-FORTUNET H , BABANY G , LETTERON P., IGLICKI F., SLAMA J L., HABERSETZER F., PESSAYRE D., BENHAMOU J.P Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients. J. Hepatol., 1989, 8 . 158-164.
72. LECLERCQ I., DESAGER J.P , VANDENPLAS C., HORSMANS Y. Fast determination of low level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance detection. J Chromatogr., 1996, 681 : 227-232.
73. LECLERCQ V., DESAGER J.P., HORSMANS Y., VAN NIEUWENHUYZE Y., HARVENGT C. Influence of rifampicin. phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. Int. J. Clin. Pharmacol. Ther. Toxicol.. 1989, 27 : 593-598.
74. LEVIN W. The 1988 Bernard B. Brodie award lecture. Functional diversity of hepatic cytochromes P-450 Drug Met. Disp., 1990, 18 : 824-830.
75. LOU Y.C. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab. Rev., 1990, 33 : 451-475.
76. MAGHOUB A., IDLE J.R., DRING L.G., LANCASTER R , SMITH R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet, 1977, 2 : 584-586.
77. MARTI U., HAURI H.P., MEYER U.A Induction of cytochrome P450 by phenobarbital in liver vizualized by monoclonal antibody immuno electron microscopy. Eur J. Cell. Biol , 1990, 52 : 193-200.
78. MC KINNON R A., BURGESS W.M., HALL P.M., ABDUL-AZIZ Z., MC MANUS M.E. Metabolism of food-derived heterocyclic amines in human and rabbit tissues by P4503A proteins in presence of flavonoids. Cancer Res., 1992, 52 (Suppl) : 2108-2113.
79. MEYER U.A. The molecular basis of genetic polymorphisms of drug metabolism. J. Pharm. Pharmacol., 1994, 46 (Suppl) : 409-415.
80. MIRANDA A.L., REED R L , GUENGERICH F.P., BUHLER D.R. Role of cytochrome P450IIIA in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. Carcinogenesis, 1991, 12 515-519.
81. MORGAN M.Y., RESHEF R., SHAH R R., OATES N.S , SAITH R.E., SHERLOCK S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut, 1984, 25 1057-1064.
82. MORGAN D J., SMALLWOOD R.A. Clinical significance of pharmacokinetic models of hepatic elimination. Clin. Pharmacokinet., 1990, 18 . 61-76.
83. NAKAMURA K., GOTO F., RAY W.A., McALLISTER C.B., JACQZ E., WILKINSON G R., BRANCH R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther., 1985, 38 . 402-408.
84. NEBERT D.W., NELSON D R , COON M.J. ESTABROOK R.W., FEYEREISEN R., FUJII-KURIYAMA Y, GONZALEZ F.J., GUENGERICH F.P., GUNSALUS I.C., JOHNSON E.F., LOPER J.C , SATO R., WATERMAN M.R., WAXMAN M.R. The P450 superfamily update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology, 1991, 10 : 1-14.
85. NELSON D.R., KAMATAKI T , WAXMAN D.L., GUENGERICH F-P , ESTABROOK R. W. The P450 superfamily : update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 1993, 12 : 1-51.
86. OKADA T., KAWASHIMA K., FUKUSHI S., MINAKUCHI T., NISHIMURA S. Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer Pharmacogenetics, 1994, 4 . 333-340
87. OKUNO H., KITAO Y., TAKASU M., KANO H., KUNIEDA K., SEKI T. Depression of drug metabolizing activity in the human liver by interferon-α. Eur. J. Clin. Pharmacol., 1990, 39 : 365-67.
88. OKUNO H., TAKASU M., KANO H., SEKI T., SHIOZAKI Y., INOU E K. Depression of drug-metabolizing activity in the human liver by interferon-β. Hepatology. 1993, 17 : 65-69.
89. OHNISHI K., IIDA S., IWAMA S. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma. Cancer, 1982, 49 : 672-674.
90. PAGE M A , BOUTAGY J.S , SHENFIELD G.M. A screening test for slow metabolizers of tolbutamide. Br. J. Clin. Pharmacol., 1991, 31 : 649-654
91. 14C aminopyrine in liver diseases. Dig. Dis. Sci., 1982, 27 49-56
92. PESSAYRE D , LARREY D. Acute and chronic drug-induced hepatitis Baillière's Clinical Gastroenterology, 1988, 2 : 385-422.
93. POPPER H. The increasing importance of liver tumors. In : Primary Liver Tumors. REMMER H., BOLT H.M., BANNASCH P , POPPER H. (eds) Lancaster, MTP Press. 1978 ; 3-10 and 495-503.
94. 13C-[N-3- methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther., 1992, 52 : 170-180.
95. SAURAI M., MIYAJI T. Orcein staining of hepatitis B surface antigen in paraffin sections of liver on autopsy cases Hepato-Gastroenterol., 1977, 24 : 334-339.
96. SCHELLENS J.H.M., SOONS P.A , BREIMER D.D. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem. Pharmacol., 1988, 37 : 2507-2510.
97. SHAND O.G., KORNHAUSER D.M., WILKINSON G.R. Effect of route of administration and blood flow on hepatic drug elimination J. Pharmacol. Exp. Ther , 1975, 195 : 416-423.
98. STAUBLI W., HESS R., WEIBEL E.R Correlated morphometric and biochemical studies on the liver cell II Effects of phenobarbital on rat hepatocytes. J. Cell. Biol., 1969, 42 : 92-112.
99. STEIN O., FAINARU M., STEIN Y. Visualisation of virus-like particles in endoplasmic reticulum of hepatocytes of Australia antigen carriers Lab. Invest., 1972, 26 262-269.
100. TASSANEEYAKUL W., VERONESE M.E., BIRKETT D.J. et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br. J. Clin. Pharmacol , 1992, 34 : 494-498
101. THUMMEL K.E., SHEN D.D., PODOLL T.D , KUNZE K.L , TRAGER W F , BACCHI C.E , MARSH C L , MCVICAR J.P , BARR D M , PERKINS J.D , WATKINS P.B. Use of midazolam as a human cytochrome P450 3A probe . H. Characterization of inter- and intra-individual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp Ther., 1994, 271 . 557-566
102. TINEL M., BHLGHITI J., DESCATOIRE V , AMOUYAL G., LETTERON P., LARREY D , PESSAYRE D Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives Biochem. Pharmacol., 1987, 36 : 951-955.
103. TURGEON D.K , NORMOLLE D.P., LEITCHMAN A B , ANNESLEY T.M., SMITH D.E., WATKINS P.B. Erythromycin breath test predicts oral clearance of cyclosporine A in renal transplant recipients. Clin. Pharmacol. Ther., 1992, 52 : 471-478.
104. VERMEIJ P., FERRARI M.D , BURUMA O J., VEENEMA H., DE WOLF F.A. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol. Ther , 1988, 44 : 588-593.
105. WAHLLAENDER A., MOHR S., PAUMGARTNER G. Assessment of hepatic function : comparison of caffeine clearance in serum and saliva during the day and at night. J. Hepatol., 1990, 10 : 129-137.
106. WATANABE J., KANAMURA S. An improved microphotometry system for measurement of cytochrome P-450 in hepatocyte cytoplasm. J Hislochem. Cytochem., 1991, 39 : 689-694.
107. WATKINS P.B., HAMILTON T.A., ANNESLEY T.M., ELLIS C.N., KOLARS J.C., VOORHEES J.J. The erythromycin breath test as a predictor of cyclosporine blood levels Clin. Pharmacol. Ther., 1990. 48 : 120-129.
108. WATKINS P.B. Non-invasive tests of CYP3A enzymes Pharmacogenetics, 1994, 4: 171-184.
109. WATSON R.G., OLOMU A , CLEMENTS D., WARING R.H., ELIAS E. A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation. J. Hepatol., 1988, 7 : 72-78.
110. WEDLUND P.J , ASLANIAN W.S , MC ALLISTER C.B., WILKINSON G.R. Mephenytoin hydroxylation deficiency in Caucasians frequency of a new oxidative drug metabolism polymorphism Clin. Pharmacol Ther., 1984, 36 773-780.
111. WILLIAMS S.J , FARRELL G.C. Inhibition of antipyrine metabolism by interferon. Br. J. Clin. Pharmacol., 1986, 22 610-612.
112. WILLIAMS S J., BAIRD-LAMBERT J.A., FARRELL G.C. Inhibition of theophylline metabolism by interferon. Lancet, 1987, 2 : 939-941
113. WRIGHTON S.A., RING B J., WATKINS P B., VANDENBRANDEN M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol., 1989, 36 : 97-105.
114. YEE G.C , MC GUIRE T R. Pharmacokinetic drug interactions with cyclosporin (Part I and II). Clin. Pharmacokinet., 1990, 19 . 319-332 and 400-415.
115. YUE Q.Y., SVENSSON J.O., ALM C., SJÖQVIST F., SÄWE J. Codeine Odemethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin Pharmacol., 1989, 28 : 639-645.
116. ZANGER U.M , HAURI H.P , LOEPER J., HOMBERG J.C., MEYER U.A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc. Natl Acad. Sci USA, 1988, 85 . 8256-8260.
117. ZIMMERMAN H.J., MADDREY W C. Acetaminophen (Paracetamol) hepatotoxicity with regular intake of alcohol. analysis of instances of therapeutic misadventure. Hepatology, 1995, 22 . 767-773.